Form 4 for ANAB ANAPTYSBIO, INC
Accepted 2023-09-18 00:00:00 ET · period of report 2023-09-14 · accession 0001209191-23-049808 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-09-18 | 2023-09-14+ | ANAB | MULROY DENNIS | CFO | S - Sale+OE | $19.38 | -6,000 | 4,859 | -55% | -$116.3K |
| D | 2023-09-18 | 2023-09-14 | ANAB | MULROY DENNIS | CFO | M - OptEx | — | +6,000 | 6,964 | +622% | — |
| D | 2023-09-18 | 2023-09-14 | ANAB | MULROY DENNIS | CFO | M - OptEx | $0.00 | -6,000 | 6,000 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-18 | S | D | 3,895 | $19.32 | 964 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.145 to $19.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 2 | Common | Common Stock | 2023-09-14 | M | A | 6,000 | — | 6,964 | D | — | — | (F1) Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. |
| 3 | Common | Common Stock | 2023-09-14 | S | D | 2,105 | $19.48 | 4,859 | D | — | — | |
| 4 | Derivative | Restricted Stock Unit | 2023-09-14 | M | D | 6,000 | $0.00 | 6,000 | D | — · — to — | 6,000 Common Stock | (F1) Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. (F5) 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |